X-Linked Retinitis Pigmentosa (XLRP) Overview

Save information for later
Sign Up

Learn About X-Linked Retinitis Pigmentosa (XLRP)

View Main Condition: Retinitis Pigmentosa

What is the definition of X-Linked Retinitis Pigmentosa (XLRP)?
X-linked retinitis pigmentosa is a type of inherited eye disorder that affects the retina, causing progressive vision loss. X-linked retinitis pigmentosa is classified as non-syndromic because it occurs by itself instead of as part of other syndromes.
What are the symptoms of X-Linked Retinitis Pigmentosa (XLRP)?
Symptoms of X-linked retinitis pigmentosa include a loss of night vision in childhood; blind spots in the side, or peripheral, vision; tunnel vision; loss of central vision; and, eventually, blindness.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for X-Linked Retinitis Pigmentosa (XLRP)?
Treatment for X-linked retinitis pigmentosa involves the use of gene therapy made from adeno-associated viral vectors.
Who are the top X-Linked Retinitis Pigmentosa (XLRP) Local Doctors?
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Alessandro Iannaccone
Ophthalmology
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Alessandro Iannaccone
Ophthalmology

University Of North Carolina At Chapel Hill

2226 Nelson Hwy, Suite 200, 
Chapel Hill, NC 
984-974-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alessandro Iannaccone is an Ophthalmologist in Chapel Hill, North Carolina. Dr. Iannaccone is rated as an Elite provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, X-Linked Retinitis Pigmentosa (XLRP), and Usher Syndrome Type 2A. Dr. Iannaccone is currently accepting new patients.

Elite in X-Linked Retinitis Pigmentosa (XLRP)
Michel Michaelides
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Michel Michaelides
City Road, 
London, ENG, GB 

Michel Michaelides practices in London, United Kingdom. Mr. Michaelides is rated as an Elite expert by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are Retinopathy Pigmentary Mental Retardation, Color Blindness, Retinitis Pigmentosa, Vitrectomy, and Cataract Removal.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Byron L. Lam
Ophthalmology
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Byron L. Lam
Ophthalmology

University Of Miami

900 Nw 17th St, 
Miami, FL 
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Byron Lam is an Ophthalmologist in Miami, Florida. Dr. Lam is rated as an Elite provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Optic Nerve Atrophy, Vitrectomy, and Nerve Decompression. Dr. Lam is currently accepting new patients.

View All Doctors
What are the latest X-Linked Retinitis Pigmentosa (XLRP) Clinical Trials?
An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2

Summary: The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Biological
Study Phase: Phase 2

Summary: The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

View All Clinical Trials